We are a clinical-stage biopharmaceutical company engaged in the discovery and development of a novel class of therapeutics using our proprietary small molecule nucleic acid hybrid (SMNH) chemistry platform. SMNH compounds are small segments of nucleic acids that we design to selectively target and modulate the activity of specific proteins implicated in various disease states. Our most advanced SMNH product candidate, inarigi...
We are a clinical-stage biopharmaceutical company engaged in the discovery and development of a novel class of therapeutics using our proprietary small molecule nucleic acid hybrid (SMNH) chemistry platform. SMNH compounds are small segments of nucleic acids that we design to selectively target and modulate the activity of specific proteins implicated in various disease states. Our most advanced SMNH product candidate, inarigivir soproxil (formerly referred to as SB 9200), is being developed for the treatment of viral diseases, including hepatitis B virus (HBV).
Sponsored Ad
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.